Biodel Inc (BIOD) 0.41 $BIOD nLife Therapeutics appoints

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biodel Inc (BIOD) 0.41 $BIOD

nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 51.51 (+1.28), TRGT: 0.96 (-1.25), CBIO: 1.44 (-0.05), PTN: 0.70 (-0.11), IDXX: 93.51 (-0.28), BIOD: 0.41 (-0.03)

The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie
Zacks Equity Research - Zacks Investment Research - Thu May 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie
ABBV: 66.94 (+0.71), BIOD: 0.41 (-0.03), XNPT: 7.07 (+0.05)

Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 98.20 (+1.20), HZNP: 18.89 (-0.40), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), ACOR: 25.13 (-0.15), BIOD: 0.41 (-0.03), XNPT: 7.07 (+0.05)

Stock to Watch: Biodel Up 30.7% (BIOD)
Comtex SmarTrend(R) - Wed May 25, 8:50AM CDT
Biodel (NASDAQ:BIOD) is one of today's best performing penny stocks, up 30.7% to $0.50 on 2.6x average daily volume. Biodel has traded 2.7 million shares thus far today, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (30.7% to the Dow's 0.6%) and outperformed the S&P 500 (30.7% to the S&P's 0.5%) during today's trading.
BIOD: 0.41 (-0.03)

Biodel/Albireo Limited to Combine; Focus on Liver Diseases
Zacks Equity Research - Zacks Investment Research - Wed May 25, 8:38AM CDT
Biodel (BIOD) entered into a definitive share exchange agreement to combine with Albireo Limited.
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), BMY: 76.19 (+1.38), BIOD: 0.41 (-0.03)

Biodel Inc. and Albireo Limited Agree to Combine
Marketwired - Tue May 24, 7:05PM CDT
DANBURY, CT and BOSTON, MA--(Marketwired - May 24, 2016) - Biodel Inc. (NASDAQ: BIOD)
BIOD: 0.41 (-0.03)

AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 57.05 (+0.08), SCMP: 11.89 (+0.14), SCLN: 10.88 (+0.32), BIOD: 0.41 (-0.03)

Biodel Reports Second Quarter Fiscal Year 2016 Financial Results
Marketwire Canada - Mon May 09, 4:00PM CDT
DANBURY, CT--(Marketwired - May 09, 2016) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the second fiscal quarter ended March 31, 2016.
BIOD: 0.41 (-0.03)

Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 194.00 (-0.12), ICPT: 169.72 (-3.31), BIOD: 0.41 (-0.03), NKTR: 17.76 (+0.47)

Radius Health (RDUS) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:54PM CDT
Radius Health, Inc. (RDUS) posted a loss of 94 cents per share in the first quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of 83 cents and the year-ago loss of 47 cents
RDUS: 47.01 (-0.11), SHPG: 194.00 (-0.12), BIOD: 0.41 (-0.03), NKTR: 17.76 (+0.47)

Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 83.18 (+0.29), BIOD: 0.41 (-0.03), CLBS: 5.70 (+0.16), ARGS: 5.31 (+0.05), AZN: 33.84 (-0.30), CGEN: 6.91 (+0.26), ATHX: 2.17 (-0.05)

Type 2 Diabetes Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/82p26k/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetesand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 DiabetesOverview - Therapeutics Development - Pipeline Products for Type 2 Diabetes- Overview - Pipeline Products for Type 2 Diabetes- Comparative Analysis - Type 2 Diabetes- Therapeutics under Development by Companies - Type 2 Diabetes- Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type 2 Diabetes- Products under Development by Companies - Type 2 Diabetes- Products under Investigation by Universities/Institutes - Type 2 Diabetes- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - Addex Therapeutics Ltd - Adocia - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - Alchemia Limited - Alize Pharma SAS - AlphaMab Co., Ltd - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Arisaph Pharmaceuticals, Inc. - ArisGen SA - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Beta-Cell NV - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLingus AG - BioRestorative Therapies, Inc. - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/82...2_diabetes
AMBX: (), AMGN: 174.16 (+2.13), BIOD: 0.41 (-0.03), AZN: 33.84 (-0.30), ARRY: 4.22 (+0.48)

Conatus Up on Fast Track Status for Emricasan in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:40PM CST
Shares of Conatus Pharmaceuticals Inc. (CNAT) soared 22.5% after the company announced that the FDA has granted Fast Track designation to the company's lead pipeline candidate, emricasan,
CNAT: 2.29 (+0.03), CORT: 5.77 (-0.03), PCRX: 37.58 (+1.33), BIOD: 0.41 (-0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 9

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 35

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 148

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 32

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into GoHealth, Inc. Sparks Investor Concerns

Updated Category News Views 354

GoHealth, Inc. Under Investigation for Alleged Securities Fraud Pomerantz LLP has initiated an investigation regarding potential claims involving investors of GoHealth, Inc. (NASDAQ: GOCO). This probe aims to determine whether the company and some of its executives have participated in misleading practices concerning their financial statements. The firm is reaching out to...

Continue Reading
Exploring the Features of the 2026 Toyota GR Corolla

Updated Category News Views 334

Unleashing the Adventure with the 2026 Toyota GR Corolla Get ready for an adventurous experience with the all-new 2026 Toyota GR Corolla. Engineered to perfection, this vehicle is equipped with the innovative GR-FOUR All-Wheel Drive System, making it a formidable companion whether you're racing on the track or maneuvering through rugged terrains. The GR Corolla is...

Continue Reading
Tandem Diabetes Care Boosts Sales Guidance After Q3 Success

Updated Category News Views 65

Tandem Diabetes Care Reports Impressive Q3 Financial Results Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading name in insulin delivery and diabetes management technology, has reported its financial accomplishments for the third quarter of 2024. Following an exceptional performance, the company has also increased its sales guidance for the upcoming fiscal year. Key...

Continue Reading
Green IT Services Growth: A Comprehensive Market Overview

Updated Category News Views 193

Green IT Services Market: A Dynamic Overview The evolution of technology is more than just a trend; it represents a paradigm shift towards sustainability. As organizations embrace digital transformation, the focus on Green IT services has rapidly gained importance. The latest analyses indicate that the Green IT Services market, valued at USD 18.8 billion in recent years,...

Continue Reading
Duke Energy's Response to Hurricane Helene's Aftermath

Updated Category News Views 558

Hurricane Helene Aftermath and Power Restoration Efforts Following the severe impact of Hurricane Helene, Duke Energy (NYSE: DUK) has made remarkable progress in restoring electrical services to over 2.16 million customers. Despite these extensive restoration efforts, around 334,000 customers are still without power, largely in Upstate South Carolina and the mountainous...

Continue Reading